In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nouscom Aims To Ride Neoantigen Cancer Vaccine Wave

Executive Summary

Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform. 

You may also be interested in...



More Encouraging Data For Moderna And Merck & Co’s Personalized Cancer Therapy

A therapy individualized to each patient’s cancer has produced encouraging three-year data – though talk of accelerated approval remains a moot point.

Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions

After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel